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Long-term follow-up after 
resection of thyroid metastases 
from hepatocellular carcinoma 
in noncirrhotic liver 
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SUMMARY
Thyroid metastasis from hepatocellular carcinoma (HCC) is rare, and has poor prognosis. We 
report the case of a 62-year-old woman seen at our clinic because of the occurrence of a slightly 
painful abdominal mass. At that time, alpha-fetoprotein concentration was very high, reaching 
49,831.7 ng/mL. Abdominal ultrasound showed a heterogeneous mass in segment IV of the liver, 
which was diagnosed as HCC upon MRI. The patient underwent surgical resection and histological 
analysis of the specimen confirmed HCC. Metastases to the thyroid were detected 17 months after 
liver resection. Although the presence of metastases indicates advanced disease, thyroidectomy 
was performed, since no other distant metastases were detected. In fact, the patient is doing well 
3 years after thyroidectomy and regular imaging exams showed no tumor recurrence. Current 
alpha-fetoprotein concentration is 8 ng/mL. In conclusion, thyroid metastasis from HCC is un-
common and short-term survival is expected. However, surgical resection should be encouraged, 
especially in the case of solitary metastases. Arq Bras Endocrinol Metab. 2013;57(4):327-31
SUMÁRIO
As metástases de carcinoma hepatocelular (CHC) em tiroide são raras e o prognóstico é ruim. 
Relatamos o caso de uma paciente de 62 anos de idade atendida em nossa clínica devido a uma 
massa abdominal levemente dolorida. Naquele momento, a concentração de alta-fetoproteína 
era muito alta, chegando a 49.831,7 ng/mL. O ultrassom de abdômen mostrou uma massa he-
terogênea no segmento IV do fígado, que foi diagnosticada como CHC por meio de ressonância 
magnética. A paciente foi submetida a uma ressecção cirúrgica, e a análise histológica do espé-
cime confirmou o CHC. As metástases na tiroide foram detectadas 17 meses após a ressecção 
do fígado. Embora a presença de metástases indique doença avançada, a tiroidectomia foi feita 
porque não foram detectadas outras metástases distantes. De fato, três anos após a tiroidecto-
mia, a paciente está bem e os exames de rotina mostraram não haver recorrência do tumor. A 
concentração atual de alfa-fetoproteína é de 8 ng/mL. Concluiu-se que as metástases de CHC em 
tiroide não são comuns e espera-se uma sobrevida curta. Entretanto, deve-se encorajar a ressec-
ção cirúrgica, especialmente no caso de metástases solitárias. Arq Bras Endocrinol Metab. 2013;57(4):327-31
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INTRODUCTION
H epatocellular carcinoma (HCC) is the most com-mon primary tumor of the liver and is respon-
sible for more than 250,000 deaths worldwide every 
year (1). The natural history of HCC is devastating and 
mean survival is less than 1 year if untreated (2). Liver 
transplant and resection are considered to be curative 
treatments. Other therapeutic options exist, such as lo-
coregional and systemic treatment. Locoregional treat-
ment is a good choice and has been widely used with 
good response in terms of survival and maintenance of 
the patient on the liver transplant waiting list (3). Cur-
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rent systemic treatment is rapidly advancing but, so far, 
it has only shown slight increase in survival (4,5). Short 
survival is observed for patients with distant metastases, 
even with the current treatments. The most common 
sites of metastases from HCC are the lungs, intra-ab-
dominal lymph nodes, and bones (6,7). Many patients 
with metastases are in an advanced stage of liver disease; 
only few curative treatment options exist in these cases, 
and the prognosis is poor (8).
We report the rare case of a patient with HCC me-
tastasizing to the thyroid after hepatectomy, and who 
presented a favorable clinical outcome after metastasis 
resection.
CASE REPORT
A 62-year-old woman sought the liver transplant service 
in September 2006 because of the occurrence of a slightly 
painful abdominal mass 6 months earlier. An abdominal 
ultrasound scan performed in August 2006 showed liver 
with preserved shape and size, slightly irregular contour, 
and finely heterogenous echotexture. A hyperechogenic 
and heterogenous mass with partially defined margins 
and lobulated contour, measuring 7.3 x 5.8 x 5.4 cm, 
was detected in segment IV. The clinical history of the 
patient included thyroid goiter since 1970, and blood 
transfusion in 1986 due to an ectopic pregnancy. The 
patient reported no excessive alcohol consumption, use 
of medications, diabetes, high blood pressure, or dysli-
pidemia. General health status was good, and physical 
examination showed slightly enlarged thyroid due to 
goiter, and a hard abdominal mass with ill-defined mar-
gins located in the right upper quadrant. The body mass 
index of the patient was 22 kg/m2.
Laboratory analysis of serum parameters showed 
the following results: aspartate aminotransferase, 114 
IU/L; alanine aminotransferase, 220 IU/L; alkaline 
phosphatase, 338 IU/L; gamma-glutamyltransferase, 
178 IU/L; albumin, 4.2 g/dL; prothrombin time, 
11.2 seconds; hemoglobin, 13.4 g/dL, and plate-
let count, 283,000/μL. Thyroid function tests were 
normal. Serum alpha-fetoprotein was extremely high 
(12,070.9 ng/mL), reaching 49,831.7 ng/mL. Sero-
logy for hepatitis B and C virus was negative. No HCV 
RNA was detected by PCR. Serum iron tests were nor-
mal. Autoantibodies were negative.
Magnetic resonance imaging (MRI) of the abdo-
men performed 3 months later revealed the presence of 
three nodular formations in the liver, which presented 
the following characteristics: one nodular formation 
with well-defined margins and regular contour, mea-
suring approximately 7.7 x 3.8 cm, located in segment 
IV. Contrast injection revealed early enhancement (ar-
terial phase) associated with late capsule enhancement. 
Washout of tumor contrast material was seen on equili-
brium-phase image. The findings indicated HCC. The 
two other nodular areas measuring 2.3 x 1.9 cm and 
0.9 x 0.8 cm, respectively, were located in segments 
II and VIII. Contrast injection revealed globule-like 
enhancement from the periphery to the center. The 
latter image probably corresponded to hemangiomas. 
A workup for distant metastases including compu-
ted tomography (CT) of the lungs. 99mTc bone scinti-
graphy was negative.
The tumor was treated by transcatheter arterial em-
bolization (TACE), which reduced its size (Figure 1A-
B). However, the patient became intolerant after two 
sections of TACE, and the treatment was discontinued. 
After discussion of the case by radiologists, surgeons 
and physicians, the patient was placed on the liver 
transplant list. However, while waiting for a liver trans-
plant, liver function tests remained normal and there 
was no evidence of portal hypertension or distant me-
Figure 1. (A) Digital angiogram showing hypervascular liver nodule with 
diffuse lipiodol retention. (B) Axial computed tomography images showing 
a hepatic nodule in segment IV with homogenous and complete 
opacification and the presence of lipiodol. 
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tastases. New discussion of the case led to the decision 
on hepatectomy. Anatomopathological examination of 
the partial hepatectomy specimen confirmed the diag-
nosis of HCC and showed a tumor measuring 3.5 cm 
in diameter (Figure 2A). The tumor grade was 2 accor-
ding to the classification of Edmondson and Steiner. 
No microvascular invasion was observed and analysis 
of tumor-free liver samples showed steatohepatitis with 
an NAFLD activity score of 4 (Figure 2B-C) (9). TNM 
staging was pT1, pNx, pMx. Other findings included a 
cavernous hemangioma measuring 2.5 cm in diameter. 
No liver cirrhosis, cholestasis, or portal vein thrombosis 
were found. 
After liver resection, the patient developed an in-
tra-abdominal abscess that was treated using drainage 
and antibiotics. The patient required several months to 
recover. Serum alpha-fetoprotein levels continued to 
be high (> 30,000 ng/mL), although no liver, lymph 
node, bone, or lung metastases could be detected by 
imaging exams. Seventeen months later, the patient 
complained of mild dysphagia and enlarged neck, whi-
ch was identified by fine-needle aspiration as a secon-
dary focus of HCC. 
Since no further metastases were detected outside the 
liver, the patient recovered well from surgery, and there 
was no recurrence of HCC in the liver, solitary metastases 
in the thyroid were suspected and the patient underwent 
total thyroidectomy. Anatomopathological examination 
showed a thyroid gland weighing 362 g and measuring 
16.0 x 11.3 x 5.5 cm, and two nodules compatible with 
colloid goiter. There were two other metastatic nodu-
les, the larger one measuring 7.5 x 5.0 cm. Tumor cells 
showed a distinctive histologic trabecular pattern (Figure 
3A). Immunohistochemical staining showed that tumor 
cells were positive for monoclonal antibody HepPar-1 
(Figure 3B), anticytokeratin (CAM-5.2), CD-10 (Figure 
3C), and polyclonal antiserum to carcinoembryonic an-
tigen (pCEA). However, neoplastic cells were negative 
for thyroglobulin and thyroid transcription factor 1. The 
immunological feature established the diagnosis of me-
tastatic HCC to the thyroid (Figure 3).
Despite her advanced clinical disease, the patient is 
doing surprisingly well, and no recurrence of the tumor 
was detected by regularly imaging exams (MRI and 
bone scan) 3 years after thyroidectomy. In addition, al-
pha-fetoprotein concentration decreased to 8 ng/mL 
and continues to be normal.
DISCUSSION
Liver cancer is the third leading cause of cancer-related 
death, exceeded only by cancer of the lungs and stoma-
ch. HCC typically occurs in the setting of liver cirrhosis, 
especially when associated with hepatitis C or B virus 
infection and alcoholic cirrhosis. The development of 
metastases results in a poor prognosis. We report here 
the case of a patient with metastases to the thyroid that 
presented a long-term follow-up after resection. The 
clinical evolution of the patient has been satisfactory 4 
years after tumor resection and 3 years after metastasis 
resection, without apparent recurrence of the tumor in 
the liver or other organs. 
Figure 2. High-power microscopic view of liver slides showing: (A) 
Encapsulated hepatocellular carcinoma. Note the compact pattern with 
compressed sinusoids (H&E). (B) Mild nonalcoholic steatohepatitis with 
steatosis in zone 3, hepatocyte ballooning degeneration (H&E). (C) 
Perisinusoidal collagen deposition in zone 3 (reticulin). 
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The most common sites of HCC metastases are the 
lungs (> 50%), abdominal lymph nodes (41%), and bo-
nes (28%) (6). The adrenal glands are also frequently 
affected (6,10). Metastases to the thyroid are rare and 
few cases have been reported in the literature. In fact, 
we found only four other cases of HCC with thyroid 
metastases prior to the present case (11-13). Therefore, 
the differential diagnosis with primary thyroid tumor is 
mandatory. In the present case, histological and immu-
nohistochemical analysis of the surgical thyroid speci-
men left no doubts about the diagnosis of metastatic 
HCC. 
The suspicion of metastases from HCC to the 
thyroid is very difficult due to the lack of symptoms, 
a fact that delays the diagnosis. Toshima and cols. (14) 
reported a similar case of a 74-year-old man who under-
went hepatectomy for HCC. About 22 months later, 
des-gamma-carboxy prothrombin levels were elevated 
in the presence of normal alpha-fetoprotein. However, 
no recurrent HCC was detected using contrast-enhan-
ced CT, bone scintigraphy, and upper gastrointestinal 
endoscopy. Physical examination revealed no palpable 
neck nodule and the patient had no symptoms. Only 
fluorine-18 fluorodeoxyglucose positron emission to-
mography/computed tomography (FDG-PET/CT) 
was able to detect a small nodule in the thyroid, which 
was confirmed to be metastatic HCC by fine needle 
biopsy. In the present case, alpha-fetoprotein levels re-
mained high after hepatectomy, a finding that suggests 
the presence of a synchronous tumor, but this suspi-
cion was not confirmed by imaging exams, although no 
PET/CT scan had been done. After 17 months, the 
patient complained of dysphagia when a new thyroid 
nodule was detected, and the biopsy confirmed a metas-
tatic HCC to the thyroid. It is likely that the tumor was 
already present when the hepatectomy was performed.
The natural history of metastatic HCC is very short 
survival, and current treatments are somehow ineffec-
tive. Liang and cols. (12) reported a case of HCC me-
tastases to the thyroid and lymph node involvement in 
a 54-year-old man who remained alive only about 8 
months after thyroidectomy. At that time, liver HCC 
had relapsed. Advanced thyroid involvement and recur-
rence of HCC in the liver might have contributed to 
the short survival even after thyroid resection. In con-
trast, the present patient had no lymph node involve-
ment, there was no recurrence of HCC in the liver, and 
the metastases to the thyroid appeared to be solitary. 
In addition, there was no evidence of liver cirrhosis and 
liver function was preserved as confirmed by serum li-
ver function tests. In fact, the patient became symp-
tom-free after thyroidectomy, serum alpha-fetoprotein 
levels decreased to the normal range, and subsequent 
imaging exams found no evidence of tumor recurrence 
in the liver or at any other distant sites. Therefore, the 
patient continues to be alive and tumor-free 3 years af-
ter thyroidectomy. 
Figure 3. High-power microscopic view of thyroid slides showing: (A) 
Metastatic hepatocellular carcinoma (left) in thyroid (right) H&E. (B) 
Cytoplasmic HepPar-1 staining on tumor cells (arrow). (C) CD10 
immunostaining of bile canaliculi (arrows).
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We reported a rare case of HCC in noncirrhotic li-
ver and metastases to the thyroid in a 62-year-old wo-
man, who presented an excellent unusual evolution. 
Complete resection of both the liver tumor and thyroid 
metastases solved the symptoms, and there were no 
signs of recurrence of the tumor. Therefore, surgical 
approach of solitary metastases from HCC may be con-
sidered, since it may prolong patient survival. 
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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